论文部分内容阅读
目的评价骨桥蛋白(OPN)作为肿瘤血清标记物在胰腺癌诊断中的作用。方法收集北京协和医院胰腺外科2004年2月至2006年2月相关临床住院病人的血清64例,运用ELISA法检测其中的46例胰腺癌病人、18例慢性胰腺炎病人以及20名健康人的血清中的OPN、CA19-9和CA242的含量。用ROC曲线法对检测结果进行分析,同时对结果进行统计学检验。结果三种肿瘤标记物的水平在胰腺癌组均高于慢性胰腺炎组,且差异均有显著性意义(P<0.01)。运用ROC曲线法对三种肿瘤标记物的检测结果进行处理。OPN、CA19-9和CA242的AUC(area under curve)分别为0.788、0.808和0.737。分层分析表明,OPN和CA19-9在手术无法切除组高于手术可切除组(P<0.01)。结论OPN在胰腺癌血清学诊断中有临床意义,若同时联合检测CA19-9,则对胰腺癌术前可切除性评估有一定的临床价值。
Objective To evaluate the role of osteopontin (OPN) as a tumor serum marker in the diagnosis of pancreatic cancer. Methods Sixty-four patients with clinical inpatients from April 2004 to February 2006 were collected from Peking Union Medical College Hospital. The serum of 46 patients with pancreatic cancer, 18 patients with chronic pancreatitis and 20 healthy persons were detected by ELISA. In OPN, CA19-9 and CA242 content. The test results were analyzed by ROC curve method, and the results were statistically tested. Results The levels of three tumor markers in pancreatic cancer group were higher than those in chronic pancreatitis group, and the difference was significant (P <0.01). Using ROC curve method to test the results of three kinds of tumor markers. The AUC (area under curve) for OPN, CA19-9 and CA242 was 0.788, 0.808 and 0.737, respectively. Hierarchical analysis showed that OPN and CA19-9 were higher in the unresectable group than in the resectable group (P <0.01). Conclusion OPN has clinical significance in serological diagnosis of pancreatic cancer. If combined with detection of CA19-9 at the same time, there is certain clinical value for the evaluation of preoperative resectability of pancreatic cancer.